Recently, the development of molecular biotechnology allows modifications of viral genomes genetically and optimizes the transformation of available viruses with weak pathogenicity. These methods are used to enhance the oncolytic effect and reduce adverse reactions to maximize both efficacy and safety. Indeed, the oncolytic virus can stimulate a pro-inflammatory tumor environment by enhancing antigen recognition and robust immune responses. It overcomes the immune evasiveness and escape of malignant cells to eliminate the tumor cells.
https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
An oncolytic virus is a form of promising therapeutic tool for the treatment of malignant tumors, which uses viruses to selectively infect and kill tumor cells and further to induce or boost specific antitumor immunity. https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
Oncolytic viruses encoding reporter genes utilized for in vivo molecular imaging are useful to locate the distribution of oncolytic viruses in pre-clinical tests. Optical detection methods mainly include green fluorescent protein (GFP), enhanced GFP (eGFP), discosoma red fluorescent protein (DsRed), and bioluminescence imaging (BLI), which utilizes luciferases. Reporter-encoding oncolytic viruses, including vaccinia virus, adenovirus, herpes simplex virus and vesicular stomatitis virus, allow accurate tracking of gene expression, tumor metastases, viral infection as well as assessment of gene therapy.
https://www.creative-biolabs.com/oncolytic-virus/category-reporter-encoding-oncolytic-virus-293.htm
Vaccinia virus can accommodate more than 30 kb of foreign DNA. Foreign genes can be stably integrated into the viral genome, resulting in efficient and long-term gene expression. The deletion of the viral genes of thymidine kinase (TK) and vaccinia growth factors (VGF) results in enhanced tumor-selectively and antitumor activity, and reduced virus virulence. https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Oncolytic viruses are a class of antitumor agents that selectively kill tumor cells without affecting normal cells. Vaccinia virus (VACV) is a large, enveloped virus that is considered as the most potential live biotherapeutic agent because of its strong oncolytic efficacy and potent antigen presentation capability that can combine well with its natural oncolytic activities for cancer immunotherapy. Many types of modified vaccinia virus have been used for in vitro and in vivo studies, as well as clinical trials.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Partial deletion of the HSV gene results in superior packaging capacity of >30 kb foreign DNA with low toxicity as an expression vector. Multiple modified purified oncolytic herpes simplex virus (oHSV) products can avoid evading the host immune response and reduce toxicity by gene knock-out, such as ICP0, ICP4, ICP22, ICP27 or ICP47.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Oncolytic viruses are using for the treatment of cancer due to the specific antitumor activity in tumor cells. Herpes simplex virus (HSV) is a human neurogenic dsDNA virus that has the characteristic of life-long latent infection of neurons and allows for long-term transgene expression.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Oncolytic viruses have the potential to powerfully and selectively kill cancer cells and have shown impressive efficacy in preclinical and clinical settings. However, their potential can be restricted by inefficient delivery into the complex tumor environment. Thus, the efficient delivery of oncolytic viruses remains a significant challenge in the field of oncology, limiting their therapeutic effect. https://www.creative-biolabs.com/oncolytic-virus/approaches-to-delivery-of-oncolytic-viruses.htm
Recently, the development of molecular biotechnology allows modifications of viral genomes genetically and optimizes the transformation of available viruses with weak pathogenicity. These methods are used to enhance the oncolytic effect and reduce adverse reactions to maximize both efficacy and safety. Indeed, the oncolytic virus can stimulate a pro-inflammatory tumor environment by enhancing antigen recognition and robust immune responses. It overcomes the immune evasiveness and escape of malignant cells to eliminate the tumor cells.
https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
An oncolytic virus is a form of promising therapeutic tool for the treatment of malignant tumors, which uses viruses to selectively infect and kill tumor cells and further to induce or boost specific antitumor immunity. https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
Oncolytic viruses encoding reporter genes utilized for in vivo molecular imaging are useful to locate the distribution of oncolytic viruses in pre-clinical tests. Optical detection methods mainly include green fluorescent protein (GFP), enhanced GFP (eGFP), discosoma red fluorescent protein (DsRed), and bioluminescence imaging (BLI), which utilizes luciferases. Reporter-encoding oncolytic viruses, including vaccinia virus, adenovirus, herpes simplex virus and vesicular stomatitis virus, allow accurate tracking of gene expression, tumor metastases, viral infection as well as assessment of gene therapy.
https://www.creative-biolabs.com/oncolytic-virus/category-reporter-encoding-oncolytic-virus-293.htm
Vaccinia virus can accommodate more than 30 kb of foreign DNA. Foreign genes can be stably integrated into the viral genome, resulting in efficient and long-term gene expression. The deletion of the viral genes of thymidine kinase (TK) and vaccinia growth factors (VGF) results in enhanced tumor-selectively and antitumor activity, and reduced virus virulence. https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Oncolytic viruses are a class of antitumor agents that selectively kill tumor cells without affecting normal cells. Vaccinia virus (VACV) is a large, enveloped virus that is considered as the most potential live biotherapeutic agent because of its strong oncolytic efficacy and potent antigen presentation capability that can combine well with its natural oncolytic activities for cancer immunotherapy. Many types of modified vaccinia virus have been used for in vitro and in vivo studies, as well as clinical trials.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Partial deletion of the HSV gene results in superior packaging capacity of >30 kb foreign DNA with low toxicity as an expression vector. Multiple modified purified oncolytic herpes simplex virus (oHSV) products can avoid evading the host immune response and reduce toxicity by gene knock-out, such as ICP0, ICP4, ICP22, ICP27 or ICP47.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Oncolytic viruses are using for the treatment of cancer due to the specific antitumor activity in tumor cells. Herpes simplex virus (HSV) is a human neurogenic dsDNA virus that has the characteristic of life-long latent infection of neurons and allows for long-term transgene expression.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Oncolytic viruses have the potential to powerfully and selectively kill cancer cells and have shown impressive efficacy in preclinical and clinical settings. However, their potential can be restricted by inefficient delivery into the complex tumor environment. Thus, the efficient delivery of oncolytic viruses remains a significant challenge in the field of oncology, limiting their therapeutic effect. https://www.creative-biolabs.com/oncolytic-virus/approaches-to-delivery-of-oncolytic-viruses.htm
Numerous viruses are being developed pre-clinically and clinically. An investigation of all registered clinical trials in 2017 demonstrates 78 interventional trials regarding OVs. This ability for near-universal therapeutic impact in cancer makes OVs a popular therapeutic tool. Today, both preclinical and early-stage clinical trials are intensively investigating the approach to improve oncolytic virotherapy.
https://www.creative-biolabs.com/oncolytic-virus/applications-of-oncolytic-viruses-in-cancer-treatment.htm
To fully optimize oncolytic virotherapy and provide meaningful mechanistic insight, it is important to have representative animal models of oncolysis in various tumor types. https://www.creative-biolabs.com/oncolytic-virus/animal-models-for-oncolytic-virus-study.htm
Abciximab (also known as abcixifiban or c7E3 Fab), is the Fab fragment of the chimeric human-murine, monoclonal antibody 7E3. It is composed of murine variable regions and human constant regions.https://www.creativebiolabs.net/abciximab-overview.htm
Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). https://www.creativebiolabs.net/abagovomab-overview.htm
Wnt comprises a diverse family of secreted lipid-modified signaling glycoproteins that are 350-400 amino acids in length. Wnt is an acronym in the field of genetics that stands for 'Wingless/Integrated'.https://www.creativebiolabs.net/wnt-signaling-pathway.htm
TNF works through two receptors, TNFR1 and TNFR2. TNFR1 is the major signal receptor of TNF-α. TNFR2, which mediates limited biological responses, binds to TNF-α and TNF-β. TNF signaling transduction through TNFR1 and TNFR2 can induce a variety of cellular responses, which depends on many factors, including the metabolic state of the cell and the adaptor proteins present in the cell.https://www.creativebiolabs.net/tnf-signaling-pathway.htm
Innate immune receptors, also known as pattern recognition receptors (PRRs), have been identified in the serum, on the cell surface, in endosomes, and in the cytoplasm. Toll-like receptors (TLRs) is one of the particularly important groups of PRRs.https://www.creativebiolabs.net/tlr-signal-pathway.htm
Transforming growth factor beta (TGF-β) is a cytokine that participates in both physiological and pathological processes.https://www.creativebiolabs.net/tgf-beta-signaling-pathway.htm
T-cell receptor (TCR) is a heterodimers composed of α and β peptide chains. TCR is mainly responsible for recognizing the antigens presented by major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APC).https://www.creativebiolabs.net/tcr-signal-pathway.htm
Ras, which is a low-molecular-weight GDP/GTP-binding guanine triphosphatase, is the prototypical member of the Ras superfamily of proteins. https://www.creativebiolabs.net/ras-signaling-pathway.htm
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which are responsible for regulating gene expression.https://www.creativebiolabs.net/ppar-signaling-pathway.htm
PI3K-Akt signaling pathway is one of the important signal transduction pathways in cells. It is involved in regulating cell metabolism, growth, proliferation, survival, transcription and protein synthesis by affecting the activation of downstream effector molecules. https://www.creativebiolabs.net/pi3k-akt-signaling-pathway.htm
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD19.
https://www.creativebiolabs.net/anti-cd19-adcc-enhanced-antibody-taplitumomab-105903.htm
Recombinant chimeric antibody expressed in CHO binding to human CAIX. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.
https://www.creativebiolabs.net/Anti-CAIX-CA9-Therapeutic-Antibody-Rencarex-13758.htm
Recombinant mouse monoclonal antibody expressed in CHO binding to human B-lymphoma cell. Detumomab is a mouse monoclonal antibody developed for the treatment of cancer.
https://www.creativebiolabs.net/Anti-B-cell-lymphomas-Therapeutic-Antibody-detumomab-326.htm
Recombinant monoclonal antibody to P. aeruginosa. Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against P. aeruginosa. It is a fully human pentameric IgM antibody with a mouse J chain.
https://www.creativebiolabs.net/Anti-B-anthracis-anthrax-protective-antigen-PA-Therapeutic-Antibody-Aerumab-11-13641.htm
Recombinant monoclonal antibody to Bacillus anthracis protective antigen. Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys.
https://www.creativebiolabs.net/Anti-B-anthracis-anthrax-protective-antigen-PA-Therapeutic-Antibody-ABthrax-13697.htm
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human AFP. Tacatuzumab is a humanized monoclonal antibody intended for the treatment of cancer.
https://www.creativebiolabs.net/anti-afp-adcc-enhanced-antibody-tacatuzumab-105879.htm
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD22.
https://www.creativebiolabs.net/anti-cd22-adcc-enhanced-antibody-inotuzumab-105908.htm
Recombinant monoclonal antibody to MMP9. Andecaliximab is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD), Colitis, ulcerative (UC), Solid tumors.
https://www.creativebiolabs.net/Andecaliximab-67638.htm
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Numerous viruses are being developed pre-clinically and clinically. An investigation of all registered clinical trials in 2017 demonstrates 78 interventional trials regarding OVs. This ability for near-universal therapeutic impact in cancer makes OVs a popular therapeutic tool. Today, both preclinical and early-stage clinical trials are intensively investigating the approach to improve oncolytic virotherapy.
https://www.creative-biolabs.com/oncolytic-virus/applications-of-oncolytic-viruses-in-cancer-treatment.htm
To fully optimize oncolytic virotherapy and provide meaningful mechanistic insight, it is important to have representative animal models of oncolysis in various tumor types. https://www.creative-biolabs.com/oncolytic-virus/animal-models-for-oncolytic-virus-study.htm
Abciximab (also known as abcixifiban or c7E3 Fab), is the Fab fragment of the chimeric human-murine, monoclonal antibody 7E3. It is composed of murine variable regions and human constant regions.https://www.creativebiolabs.net/abciximab-overview.htm
Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). https://www.creativebiolabs.net/abagovomab-overview.htm
Wnt comprises a diverse family of secreted lipid-modified signaling glycoproteins that are 350-400 amino acids in length. Wnt is an acronym in the field of genetics that stands for 'Wingless/Integrated'.https://www.creativebiolabs.net/wnt-signaling-pathway.htm
TNF works through two receptors, TNFR1 and TNFR2. TNFR1 is the major signal receptor of TNF-α. TNFR2, which mediates limited biological responses, binds to TNF-α and TNF-β. TNF signaling transduction through TNFR1 and TNFR2 can induce a variety of cellular responses, which depends on many factors, including the metabolic state of the cell and the adaptor proteins present in the cell.https://www.creativebiolabs.net/tnf-signaling-pathway.htm
Innate immune receptors, also known as pattern recognition receptors (PRRs), have been identified in the serum, on the cell surface, in endosomes, and in the cytoplasm. Toll-like receptors (TLRs) is one of the particularly important groups of PRRs.https://www.creativebiolabs.net/tlr-signal-pathway.htm
Transforming growth factor beta (TGF-β) is a cytokine that participates in both physiological and pathological processes.https://www.creativebiolabs.net/tgf-beta-signaling-pathway.htm
T-cell receptor (TCR) is a heterodimers composed of α and β peptide chains. TCR is mainly responsible for recognizing the antigens presented by major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APC).https://www.creativebiolabs.net/tcr-signal-pathway.htm
Ras, which is a low-molecular-weight GDP/GTP-binding guanine triphosphatase, is the prototypical member of the Ras superfamily of proteins. https://www.creativebiolabs.net/ras-signaling-pathway.htm
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which are responsible for regulating gene expression.https://www.creativebiolabs.net/ppar-signaling-pathway.htm
PI3K-Akt signaling pathway is one of the important signal transduction pathways in cells. It is involved in regulating cell metabolism, growth, proliferation, survival, transcription and protein synthesis by affecting the activation of downstream effector molecules. https://www.creativebiolabs.net/pi3k-akt-signaling-pathway.htm
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD19.
https://www.creativebiolabs.net/anti-cd19-adcc-enhanced-antibody-taplitumomab-105903.htm
Recombinant chimeric antibody expressed in CHO binding to human CAIX. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.
https://www.creativebiolabs.net/Anti-CAIX-CA9-Therapeutic-Antibody-Rencarex-13758.htm
Recombinant mouse monoclonal antibody expressed in CHO binding to human B-lymphoma cell. Detumomab is a mouse monoclonal antibody developed for the treatment of cancer.
https://www.creativebiolabs.net/Anti-B-cell-lymphomas-Therapeutic-Antibody-detumomab-326.htm
Recombinant monoclonal antibody to P. aeruginosa. Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against P. aeruginosa. It is a fully human pentameric IgM antibody with a mouse J chain.
https://www.creativebiolabs.net/Anti-B-anthracis-anthrax-protective-antigen-PA-Therapeutic-Antibody-Aerumab-11-13641.htm
Recombinant monoclonal antibody to Bacillus anthracis protective antigen. Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys.
https://www.creativebiolabs.net/Anti-B-anthracis-anthrax-protective-antigen-PA-Therapeutic-Antibody-ABthrax-13697.htm
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human AFP. Tacatuzumab is a humanized monoclonal antibody intended for the treatment of cancer.
https://www.creativebiolabs.net/anti-afp-adcc-enhanced-antibody-tacatuzumab-105879.htm
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD22.
https://www.creativebiolabs.net/anti-cd22-adcc-enhanced-antibody-inotuzumab-105908.htm
Recombinant monoclonal antibody to MMP9. Andecaliximab is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD), Colitis, ulcerative (UC), Solid tumors.
https://www.creativebiolabs.net/Andecaliximab-67638.htm
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).